ArticlePediatric research2026
Levothyroxine use and discontinuation in presumed congenital hypothyroidism: a 10-year nationwide cohort study.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of congenital hypothyroidism (CH) has been increasing worldwide. This large-scale population study investigated the use and discontinuation of levothyroxine in a nationwide cohort of patients with presumed CH over 10 years.
methodsDiagnostic, laboratory, and prescription codes from the National Health Insurance Service (NHIS) were used to identify patients treated for presumed CH in early life between 2008 and 2018. Healthcare utilization data were assessed for levothyroxine treatment duration and characteristics associated with treatment discontinuation.
resultsThe NHIS data identified 10,525 patients with presumed CH, whose prevalence and incidence more than doubled during the study period. The prevalence and incidence were significantly higher in preterm infants. The cumulative rates of levothyroxine discontinuation within 3, 5, and 10 years of treatment initiation were 39%, 67%, and 79%, respectively, with higher discontinuation rates observed among patients born preterm or with low birth weight. Male sex, preterm-birth, low birth weight, and prescriptions from non-metropolitan or non-general hospitals, predicted transient levothyroxine use.
conclusionThis study provides national-level estimates based on NHIS data showing an increasing number of infants diagnosed with presumed CH, with a majority eventually discontinuing levothyroxine. Further validation of NHIS data and evaluation of long-term treatment effects may improve epidemiologic research and the clinical management of CH. IMPACT: Nationwide cohort data showed a marked rise in infants treated for presumed congenital hypothyroidism, with most discontinuing levothyroxine within 3-5 years. Male sex, preterm birth, low birth weight, and prescriptions from non-metropolitan or non-general hospitals were predictors for transient treatment. Earlier and greater discontinuation rates were observed in preterm birth and low birthweight infants. This study provides large-scale, real-world evidence on long-term treatment patterns and discontinuation of levothyroxine. The findings highlight the need for validated registry data, standardized national guidelines, and outcome-based research to optimize diagnosis and management.
Identifiers
42304118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.